Belgian Recommendations for the management of anemia in patients with inflammatory bowel disease

Acta Gastro-Enterologica Belgica

Volumn 77, Issue 3, 2014, Pages 333-344

  Hindryckx, Pieter ^a   Amininejad, L ^b   van de Vijver, E ^c   Bossuyt, P ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d IMELDA HOSPITAL   (Belgium)

Author keywords

Anemia; Guidelines; Inflammatory bowel disease; Iron deficiency

Indexed keywords

CENTRAL STIMULANT AGENT; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN;

AGE DISTRIBUTION; ANEMIA; ARTICLE; BELGIAN; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KNOWLEDGE MANAGEMENT; LABORATORY TEST; MANAGED CARE; MEAN CORPUSCULAR VOLUME; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATHOGENESIS; PREGNANCY; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RETICULOCYTE HEMOGLOBIN CONTENT; SCREENING TEST; SUBSTITUTION THERAPY; TIME TO TREATMENT; ULCERATIVE COLITIS; ADULT; BELGIUM; CHILD; COMPLICATION; DISEASE MANAGEMENT; FEMALE; MALE; PRACTICE GUIDELINE; PRESCHOOL CHILD;

ADULT; ANEMIA; BELGIUM; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 84922328985     PISSN: 17843227     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet, 2012, 380: 1590-605.
2. Ordás I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative Colitis. Lancet, 2012, 380: 1606-19.
3. Kulnigg S., Gasche C. Systematic: managing anaemia in Crohn's disease. Aliment. Pharmacol. Ther., 2006, 24: 1507-23.
4. Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., Nimmo E.R. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology, 2008, 135: 1114-22.
5. Wiskin A.E., Fleming B.J., Wootton S.A., Beattie R.M. Anaemia and iron deficiency in children with inflammatory bowel disease. J. Crohns Colitis, 2012, 6: 687-91.
6. Goodhand J.R., Kamperidis N., Rao A., Laskaratos F., McDermott A., Wahed M. et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm. Bowel Dis., 2012, 18: 513-9.
7. Gerasimidis K., Barclay A., Papangelou A., Missiou D., Buchanan E., Tracey C. et al. The epidemiology of anemia in pediatric inflammatory bowel disease: prevalence and associated factors at diagnosis and follow-up and the impact of exclusive enteral nutrition. Inflamm. Bowel Dis., 2013, 19: 2411-22.
8. Pels L., Van de Vijver E., Waalkens H., Uitentuis J., Jong G., van Overbeek L. et al. Slow Hematological Recovery in Children With IBD-associated Anemia in Cases of "Expectant Management". JPGN, 2010, 51: 708-713.
9. Rejler M., Tholstrup J., Andersson-Gäre B., Spångéus A. Low prevalence of anemia in inflammatory bowel disease: a populationbased study in Sweden. Scand. J. Gastroenterol., 2012, 47: 937-42.
10. Bager P., Befrits R., Wikman O., Lindgren S., Moum B., Hjortswang H., et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scand. J. Gastroenterol., 2013, 48: 1286-93.
11. Bager P., Befrits R., Wikman O., Lindgren S., Moum B., Hjortswang H., et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand. J. Gastroenterol., 2011, 46: 304-9.
12. Ott C., Liebold A., Takses A., Strauch U.G., Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol. Res. Pract., 2012, 2012: 595-970.
13. Høivik M.L., Reinisch W., Cvancarova M., Moum B. and group, IBSEN study. Anaemia in inflammatory bowel disease: a population- based 10-year follow-up. Aliment. Pharmacol. Ther., 2014, 39: 69-76.
14. Bergamaschi G., Di Sabatino A., Albertini R., Ardizzone S., Biancheri P., Bonetti E. et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica, 2010, 95: 199-205.
15. Voegtlin M., Vavricka S.R., Schoepfer A.M., Straumann A., Voegtlin J., Rogler G. et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J. Crohns Colitis, 2012, 4: 642-8.
16. Pytrus T., Flis A., Iwańczak F., Iwańczak B. The frequency of anemia in children with newly diagnosed Crohn's disease in children. Pol. Merkur. Lekarski, 2013, 34: 263-8.
17. Evstatiev R., Alexeeva O., Bokemeyer B., Chopey I., Felder M., Gudehus M. et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol., 2013, 11: 269-77.
18. Gomollón F., Gisbert J.P. Anemia and inflammatory bowel diseases. World J. Gastroenterol., 2009, 15: 4659-65.
19. Stein J., Hartmann F., Dignass A.U. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol., 2012, 7: 599-610.
20. Basseri R.J., Nemeth E., Vassilaki M.E., Basseri B., Enayati P., Shaye O. et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J. Crohns Colitis, 2013, 7: e286-91.
21. Weiss G., Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica, 2010, 95: 175-8.
22. Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med., 2005, 352: 1011-23.
23. Moreno López R., Sicilia Aladrén B., Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J. Gastroenterol., 2009, 15: 4675-85.
24. Buck I., Morceau F., Grigorakaki C., Dicato M., Diederich M. Linking anemia to inflammation and cancer: the crucial role of TNFalpha. Biochem. Pharmacol., 2009, 77: 1572-9.
25. Taffet S.L., Das K.M. Sulfasalazine. Adverse effects and desensitization. Dig. Dis. Sci., 1983, 28: 833-42.
26. Gisbert J.P., Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am. J. Gastroenterol., 2008, 103: 1783-800.
27. WHO, UNICEF, UNU, MI. Preventing iron deficiency in women and children: background and consensus on key technical issues and resources for advocacy. Planning and Implementing National Programmes. International Nutrition Foundation (INF), Micronutrient Initiative (MI), 1998.
28. Gasche C., Berstad A., Befrits R., Beglinger C., Dignass A., Erichsen K. et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis., 2007, 13: 1545-53.
29. Reinisch W., Staun M., Bhandari S., Munoz M. State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J. Crohns Colitis, 2013, 7: 429-40.
30. Mast A.E., Blinder M.A., Gronowski A.M., Chumley C., Scott M.G. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin. Chem., 1998, 44: 45-51.
31. Munoz M., Garc 'a-Erce JA., Remacha ÇF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J. Clin. Pathol., 2011, 64: 287-96.
32. Stein J., Hartmann F., Dignass A.U. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol., 2010, 7: 599-610.
33. Wish J.B. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol., 2006, 1: S4-8.
34. Thomas C., Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin. Chem., 2002, 48: 1066-76.
35. Punnonen K., Irjala K., Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood, 1997, 89: 1052-7.
36. Briggs C. Quality counts: new parameters in blood cell counting. Int. J. Lab. Hematol., 2009, 31: 277-97.
37. Thomas C., Kobold U., Balan S., Roeddiger R., Thomas L. Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int. J. Lab. Hematol., 2011, 33: 187- 93.
38. Wells C.W., Lewis S., Barton J.R., Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm. Bowel Dis., 2006, 12: 123-30.
39. Gisbert J.P., Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am. J. Gastroenterol., 2008, 103: 1299-307.
40. Anker SD., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med., 2009, 361: 2436-48.
41. Gangat N., Wolanskyj AP. Anemia of chronic disease. Semin. Hematol., 2013, 50: 232-8.
42. Winter J.W., Gaffney D., Shapiro D., Spooner R.J., Marinaki A.M., Sanderson J.D. et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007, 25: 1069-77.
43. Kulnigg S., Stoinov S., Simanenkov V., Dudar L.V., Karnafel W., Garcia L.C. et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am. J. Gastroenterol., 2008, 103: 1182-92.
44. Lee T.W., Kolber M.R., Fedorak R.N., van Zanten S.V. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J. Crohns Colitis, 2012, 6: 267-75.
45. Werner T., Wagner S.J., Martínez I., Walter J., Chang J.S., Clavel T. et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut, 2011, 60: 325-33.
46. Zimmermann M.B., Chassard C., Rohner F., N'goran E.K., Nindjin C., Dostal A. et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am. J. Clin. Nutr., 2010, 92: 1406-15.
47. Lee T.W., Kolber M.R., Fedorak R.N., van Zanten S.V. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J. Crohns Colitis, 2012, 6: 267-75.
48. Avni T., Bieber A., Steinmetz T., Leibovici L., Gafter-Gvili A. Treatment of anemia in inflammatory bowel disease--systematic review and meta-analysis. PLoS One., 2013 Dec 2, 8 (12): e75540
49. Reinisch W., Staun M., Tandon R.K., Altorjay I., Thillainayagam A.V., Gratzer C. et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am. J. Gastroenterol., 2013, 108: 1877-88.
50. Van Assche G. Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging. Am. J. Gastroenterol., 2013, 108: 1889-90.
51. Goddard A.F., James M.W., McIntyre A.S. Guidelines for the management of iron deficiency anaemia. Gut, 2011 Oct, 60: 1309-16.
52. Evstatiev R., Marteau P., Iqbal T., Khalif I.L., Stein J., Bokemeyer B. et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology, 2011, 141: 846-53.
53. Lippi G., Franchini M., Favaloro E.J. Thrombotic complications of erythropoiesis-stimulating agents. Semin. Thromb. Hemost., 2010, 36: 537- 49.
54. García-Erce J.A., Gomollón F., Muñoz M. Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. World J. Gastroenterol., 2009, 15: 4686-94.
55. WHO. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. WorldHealth Organization, Geneva, 2011.
56. Aldrimer M., Ridefelt P., Rödöö P., Niklasson F., Gustafsson J., Hellberg D. Population-based pediatric reference intervals for hematology, iron and transferring. Scan. J. Clin. Lab. Invest., 2013, 73: 253-61.
57. Virtanan M.A., Viinikka L.U., Virtanan M.K., Svahn J.C., Anttila R.M., Krusius T. et al. Higher concentrations of serum transferring receptor in children than in adults. Am. J. Clin. Nutr., 1999, 69: 256- 60.
58. Danise P., Maconi M., Morelli G., Di Palma A., Rescigno G., Esposito C. et al. Reference limits and behavior of serum transferring receptor in children 6-10 years of age. Int. J. Lab. Hematol., 2008, 30: 306- 11.
59. Jain S., Narayan S., Chandra J., Sharma S., Jain S., Malhan P. Evaluation of serum transferring receptor and sTfR ferritin indices in diagnosing and differentiating iron deficiency anemia from anemia of chronic disease. Indian J. Pediatr., 2010, 77 (2): 179-83.
60. Parodi E., Giraudo MT., Davitto M., Ansaldi G., Mondino A., Garbarini L. et al. Reticulocyte parameters: markers of early response to oral treatment in children with severe iron-deficiency anemia. J. Pediatr. Hematol. Oncol., 2012, 34: e249-52.
61. Cangemi G., Pistorio A., Miano M., Gattorno M., Acquila M., Bicocchi M.P. et al. Diagnostic potential of hepcidin testing in pediatrics. Eur. J. Haematol., 2013, 90: 323-30.
62. Auerbach M., Rodgers G.M. Intravenous Iron. N. Engl. J. Med., 2007, 357: 93-4.
63. WHO/UNICEF/UNU: Iron deficiency anaemia: assessment,prevention and control, a guide for programme managers. WorldHealth Organization, Geneva, 2001.
64. Jharap B., de Boer N.K., Stokkers P., Hommes D.W., Oldenburg B., Dijkstra G. et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients wih inflammatory bowel disease. Gut, 2014, 63: 451-7.
65. Scholl T.O. Iron staus during pregnancy: setting the stage for mother and infant. Am. J. Clin. Nutr., 2005, 81: 1218S-1222S.